anemia%20-%20iron-deficiency%20(pediatric)
ANEMIA - IRON-DEFICIENCY (PEDIATRIC)

Iron deficiency (ID) is the most common nutritional deficiency in children & reportedly 3x more common than iron-deficiency anemia, but does not always develop into anemia.

Neonates & children may have delayed growth & development; adolescents may show decrements of learning such as behavioral abnormalities.

Iron-deficiency anemia is the most advanced stage of iron deficiency resulted from a protracted imbalance between iron intake & demand.

Characterized by low hemoglobin & hematocrit levels, reduction or depletion of iron stores, low serum iron levels & decreased transferrin saturation.

Anemia%20-%20iron-deficiency%20(pediatric) Management

Follow Up

  • There are no standard recommendations for follow up after starting iron therapy but patients who are in need of further medical attention may be referred to specialists
  • Referral is recommended if with disease progression or if with unresponsiveness to treatment
    • Obtain complete blood count (CBC) every 3 months for 1 year
    • Response to iron therapy is observed after weeks of treatment, should be asked to return for evaluation
    • Reassessment of treatment plan is advised if without favorable response
    • Consider referral to a hematologist for further investigation of the source of anemia
    • Consider referral to a gastroenterologist for treatment of underlying gastrointestinal lesions or suspected cancer and evaluation of gastrointestinal bleeding
  • Further follow-ups are not necessary if the patient is asymptomatic and the hematocrit level is normal
  • If hemoglobin and red blood cells (RBC) indices remain normal, one additional CBC should be obtained 12 months later
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, 3 days ago
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.